Leslie Chong has over 20 years of oncology experience in Phase I – III of clinical program development, including leadership role involvement in two marketed oncology products. She has deep development experience with small molecules, immunotherapies, cancer vaccines, oncolytic viral therapies, epigenetics and monoclonal antibodies.
Prior to becoming the chief executive and managing director of Imugene, Ms Chong was the senior clinical program lead at Genentech in San Francisco. Genentech is widely regarded as one of the world’s most successful biotech companies with a strong oncology franchise including the best-selling breast cancer drug Herceptin. She joined Imugene in September 2015 as chief operating officer and became chief executive in November 2016 and managing director in 2018.
